We track Lilly Asia Ventures but have little verified detail yet.
Portfolio
1 totalRecent Investment Activity
1Track record: led 0 and participated in 1 of 1 tracked venture round · 1 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Khartis Therapeutics | Series B | Participated | $50M | — | Foresite CapitalunverifiedLilly Asia VenturesunverifiedNextech InvestunverifiedForge Life Science Partners | Pulse story |
Co-Investors
2Latest Pulse
- Sep 25, 2026ADARx Prices $446M IPO, Debuts As ADRXADARx Pharmaceuticals priced an upsized $446 million IPO at $17 a share and began trading on the Nasdaq as ADRX, joining the fall biotech IPO window alongside its existing AbbVie drug partnership.→
- Aug 13, 2026Khartis Emerges From Stealth With $95M for a Thyroid PillKhartis Therapeutics emerged from stealth with $95 million in total funding, including a new $50 million Series B, to develop an oral alternative to injectable treatments for thyroid eye disease.→
Lilly Asia Ventures FAQ
What companies has Lilly Asia Ventures invested in?
Lilly Asia Ventures' portfolio includes Khartis Therapeutics.
Who does Lilly Asia Ventures co-invest with most?
In the rounds Value Add tracks, Lilly Asia Ventures most often invests alongside Foresite Capital (1 shared deal), Nextech Invest (1 shared deal).
Sources & methodologyshow
Where these figures come from
- Axiosmajor outlet1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.